vs
Side-by-side financial comparison of DMC Global Inc. (BOOM) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $143.5M, roughly 1.2× DMC Global Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -7.8%, a 9.4% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -5.8%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -7.3%).
DMC Mining Services is a mining services contractor founded in 1980 operating in Canada, the United States, Chile, and Mongolia
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BOOM vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $143.5M | $177.4M |
| Net Profit | $-11.2M | $2.9M |
| Gross Margin | 17.1% | — |
| Operating Margin | -7.8% | 3.9% |
| Net Margin | -7.8% | 1.6% |
| Revenue YoY | -5.8% | 5.0% |
| Net Profit YoY | -3871.6% | — |
| EPS (diluted) | $-0.60 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $143.5M | $196.9M | ||
| Q3 25 | $151.5M | $179.5M | ||
| Q2 25 | $155.5M | $181.1M | ||
| Q1 25 | $159.3M | $168.9M | ||
| Q4 24 | $152.4M | $187.3M | ||
| Q3 24 | $152.4M | $168.6M | ||
| Q2 24 | $171.2M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-11.2M | — | ||
| Q3 25 | $-3.1M | $5.4M | ||
| Q2 25 | $116.0K | $-4.8M | ||
| Q1 25 | $677.0K | $4.8M | ||
| Q4 24 | $296.0K | — | ||
| Q3 24 | $-101.3M | $-143.5M | ||
| Q2 24 | $4.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 17.1% | 79.5% | ||
| Q3 25 | 21.7% | 80.9% | ||
| Q2 25 | 23.6% | 77.4% | ||
| Q1 25 | 25.9% | 79.7% | ||
| Q4 24 | 20.8% | 78.7% | ||
| Q3 24 | 19.8% | 76.9% | ||
| Q2 24 | 27.1% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -7.8% | 1.2% | ||
| Q3 25 | 0.4% | 3.5% | ||
| Q2 25 | 2.5% | 4.7% | ||
| Q1 25 | 4.1% | 1.2% | ||
| Q4 24 | -0.5% | 13.2% | ||
| Q3 24 | -97.7% | -82.8% | ||
| Q2 24 | 6.8% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -7.8% | — | ||
| Q3 25 | -2.0% | 3.0% | ||
| Q2 25 | 0.1% | -2.7% | ||
| Q1 25 | 0.4% | 2.8% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | -66.5% | -85.1% | ||
| Q2 24 | 2.3% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.60 | $0.05 | ||
| Q3 25 | $-0.10 | $0.12 | ||
| Q2 25 | $-0.24 | $-0.11 | ||
| Q1 25 | $0.04 | $0.10 | ||
| Q4 24 | $-0.18 | $0.38 | ||
| Q3 24 | $-8.27 | $-3.11 | ||
| Q2 24 | $0.24 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.9M | $144.3M |
| Total DebtLower is stronger | $50.6M | — |
| Stockholders' EquityBook value | $242.1M | $653.9M |
| Total Assets | $635.8M | $1.2B |
| Debt / EquityLower = less leverage | 0.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $31.9M | $238.4M | ||
| Q3 25 | $26.4M | $246.3M | ||
| Q2 25 | $12.4M | $445.9M | ||
| Q1 25 | $14.7M | $493.6M | ||
| Q4 24 | $14.3M | $484.6M | ||
| Q3 24 | $14.5M | $453.8M | ||
| Q2 24 | $14.6M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $50.6M | $372.2M | ||
| Q3 25 | $56.5M | $376.7M | ||
| Q2 25 | $58.7M | $580.5M | ||
| Q1 25 | $72.4M | $583.4M | ||
| Q4 24 | $70.8M | $585.3M | ||
| Q3 24 | $74.2M | — | ||
| Q2 24 | $84.1M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $242.1M | $693.1M | ||
| Q3 25 | $253.0M | $727.2M | ||
| Q2 25 | $253.9M | $757.8M | ||
| Q1 25 | $253.9M | $798.5M | ||
| Q4 24 | $251.0M | $778.3M | ||
| Q3 24 | $256.5M | $749.6M | ||
| Q2 24 | $416.0M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $635.8M | $1.3B | ||
| Q3 25 | $644.1M | $1.3B | ||
| Q2 25 | $645.0M | $1.5B | ||
| Q1 25 | $670.6M | $1.6B | ||
| Q4 24 | $671.3M | $1.6B | ||
| Q3 24 | $702.0M | $1.5B | ||
| Q2 24 | $869.5M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.21× | 0.54× | ||
| Q3 25 | 0.22× | 0.52× | ||
| Q2 25 | 0.23× | 0.77× | ||
| Q1 25 | 0.29× | 0.73× | ||
| Q4 24 | 0.28× | 0.75× | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.20× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.2M | — |
| Free Cash FlowOCF − Capex | $9.6M | — |
| FCF MarginFCF / Revenue | 6.7% | — |
| Capex IntensityCapex / Revenue | 3.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $37.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $15.2M | $43.7M | ||
| Q3 25 | $18.6M | $60.8M | ||
| Q2 25 | $15.2M | $12.0M | ||
| Q1 25 | $4.5M | $35.5M | ||
| Q4 24 | $11.8M | $33.1M | ||
| Q3 24 | $19.0M | $53.9M | ||
| Q2 24 | $2.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $9.6M | $43.5M | ||
| Q3 25 | $14.4M | $57.0M | ||
| Q2 25 | $12.3M | $9.3M | ||
| Q1 25 | $709.0K | $26.9M | ||
| Q4 24 | $6.1M | $31.0M | ||
| Q3 24 | $12.9M | $49.8M | ||
| Q2 24 | $-204.0K | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 22.1% | ||
| Q3 25 | 9.5% | 31.7% | ||
| Q2 25 | 7.9% | 5.1% | ||
| Q1 25 | 0.4% | 15.9% | ||
| Q4 24 | 4.0% | 16.6% | ||
| Q3 24 | 8.5% | 29.6% | ||
| Q2 24 | -0.1% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.9% | 0.1% | ||
| Q3 25 | 2.8% | 2.2% | ||
| Q2 25 | 1.9% | 1.5% | ||
| Q1 25 | 2.4% | 5.1% | ||
| Q4 24 | 3.7% | 1.1% | ||
| Q3 24 | 4.0% | 2.4% | ||
| Q2 24 | 1.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 131.43× | — | ||
| Q1 25 | 6.63× | 7.37× | ||
| Q4 24 | 39.90× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.58× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOOM
| Dyna Energetics Segment | $68.9M | 48% |
| Other | $57.0M | 40% |
| Nobel Clad Segment | $17.7M | 12% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
